|
1
|
Roschkov S, Rebeyka D, Mah J and Urquhart
G: The dangers of cardiac myxomas. Prog Cardiovasc Nurs. 22:27–30.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilkes D, McDermott DA and Basson CT:
Clinical phenotypes and molecular genetic mechanisms of Carney
complex. Lancet Oncol. 6:501–508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Figueroa-Torres Y, Martínez-Ojeda JA,
Franqui-Rivera H, et al: Benign cardiac neoplasms: the experience
at the Cardiovascular Center of Puerto Rico and the Caribbean. PR
Health Sci J. 27:373–376. 2008.PubMed/NCBI
|
|
4
|
Wu X, Yang D, Yang Z, et al: Clinical
characteristics and long term post-operative outcome of cardiac
myxoma. EXCLI J. 11:240–249. 2012.
|
|
5
|
Barh D, Kumar A, Chatterjee S and Liloglou
T: Molecular features, markers, drug targets, and prospective
targeted therapeutics in cardiac myxoma. Curr Cancer Drug Targets.
9:705–716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chu PH, Jung SM, Yeh TS, et al: MUC1, MUC2
and MUC5AC expressions in cardiac myxoma. Virchows Arch. 446:52–55.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Orlandi A, Ciucci A, Ferlosio A, et al:
Increased expression and activity of matrix metalloproteinases
characterize embolic cardiac myxomas. Am J Pathol. 166:1619–1628.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakamoto H, Sakamaki T, Kanda T, et al:
Vascular endothelial growth factor is an autocrine growth factor
for cardiac myxoma cells. Circ J. 68:488–493. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujisawa H, Koide N, Kono T, et al:
Expression of basic fibroblast growth factor and its receptor-1 in
cardiac myxoma. J Cardiovasc Surg. 43:589–594. 2002.PubMed/NCBI
|
|
10
|
Amano J, Kono T, Wada Y, et al: Cardiac
myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc
Surg. 9:215–221. 2003.PubMed/NCBI
|
|
11
|
Uzoh CC, Holly JMP, Biernacka KM, et al:
Insulin-like growth factor-binding protein-2 promotes prostate
cancer cell growth via IGF-dependent or -independent mechanisms and
reduces the efficacy of docetaxel. Br J Cancer. 104:1587–1593.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rzucidlo EM: Signaling pathways regulating
vascular smooth muscle cell differentiation. Vascular. 17(Suppl 1):
S15–S20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perks C: The role of insulin-like growth
factor binding proteins. Neuroendocrinology. 83:154–160. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mateus C, Palangié A, Franck N, et al:
Heterogeneity of skin manifestations in patients with Carney
complex. J Am Acad Dermatol. 59:801–810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Raff SB, Carney JA, Krugman D, et al:
Prolactin secretion abnormalities in patients with the ‘syndrome of
spotty skin pigmentation, myxomas, endocrine overactivity and
schwannomas’ (Carney complex). J Pediatr Endocrinol Metab.
13:373–379. 2000.
|
|
16
|
Kurtkaya-Yapicier O, Scheithauer BW,
Carney JA, et al: Pituitary adenoma in Carney complex: an
immunohistochemical, ultrastructural, and immunoelectron
microscopic study. Ultrastruct Pathol. 26:345–353. 2002. View Article : Google Scholar
|
|
17
|
Wahdan-Alaswad RS, Song K, Krebs T, et al:
Insulin-like growth factor I suppresses bone morphogenetic protein
signaling in prostate cancer cells by activating mTOR signaling.
Cancer Res. 70:9106–9117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grimberg A: Mechanisms by which IGF-I may
promote cancer. Cancer Biol Ther. 2:630–635. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu B, Lee KW, Anzo M, et al: Insulin-like
growth factor-binding protein-3 inhibition of prostate cancer
growth involves suppression of angiogenesis. Oncogene.
26:1811–1819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waalkes S, Simon P, Hennenlotter J, et al:
Altered expression of Akt signaling pathway parameters in prostate
needle biopsies derived from benign, adjacent and cancerous tissue.
Oncol Rep. 23:1257–1260. 2010.PubMed/NCBI
|
|
22
|
Falbo V, Floridia G, Censi F, et al: Three
cases of rare salivary gland tumours: a molecular study of TP53,
CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes. Oncol
Rep. 26:3–11. 2011.PubMed/NCBI
|
|
23
|
Tserga A, Michalopoulos NV, Levidou G, et
al: Association of aberrant DNA methylation with
clinicopathological features in breast cancer. Oncol Rep.
27:1630–1638. 2012.PubMed/NCBI
|
|
24
|
Bouali S, Chrétien AS, Ramacci C, et al:
PTEN expression controls cellular response to cetuximab by
mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in
KRAS wild-type, hormone refractory prostate cancer cells.
Oncol Rep. 21:731–735. 2009.PubMed/NCBI
|
|
25
|
Jang K, Kim M, Seo HS, et al: PTEN
sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for
the blockade of cell proliferation. Oncol Rep. 24:787–793.
2010.PubMed/NCBI
|
|
26
|
Garcia JA and Danielpour D: Mammalian
target of rapamycin inhibition as a therapeutic strategy in the
management of urologic malignancies. Mol Cancer Ther. 7:1347–1354.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu XL, Yang DY, Yang ZS, et al: Effect of
IGF-1 on PI3K/PTEN signal pathway in vascular smooth muscle cell.
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 20:259–262. 2004.(In
Chinese).
|
|
28
|
Brognard J, Sierecki E, Gao T, et al:
PHLPP and a second isoform, PHLPP2, differentially attenuate the
amplitude of Akt signaling by regulating distinct Akt isoforms. Mol
Cell. 25:917–931. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao T, Brognard J and Newton AC: The
phosphatase PHLPP controls the cellular levels of protein kinase C.
J Biol Chem. 283:6300–6311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McCarty MF: Suppression of dolichol
synthesis with isoprenoids and statins may potentiate the
cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses.
56:12–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martínez-González J, Viñals M, Vidal F, et
al: Mevalonate deprivation impairs IGF-I/insulin signaling in human
vascular smooth muscle cells. Atherosclerosis. 135:213–223.
1997.PubMed/NCBI
|
|
32
|
Miraglia E, Högberg J and Stenius U:
Statins exhibit anticancer effects through modifications of the
pAkt signaling pathway. Int J Oncol. 40:867–875. 2012.PubMed/NCBI
|
|
33
|
Duncan RE, El-Sohemy A and Archer MC:
Statins and cancer development. Cancer Epidemiol Biomarkers Prev.
14:1897–1898. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonovas S, Filioussi K, Tsavaris N, et al:
Statins and cancer risk: a literature-based meta-analysis and
meta-regression analysis of 35 randomized controlled trials. J Clin
Oncol. 24:4808–4817. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.
|
|
36
|
Lutski M, Shalev V, Porath A and Chodick
G: Continuation with statin therapy and the risk of primary cancer:
a population-based study. Prev Chronic Dis. 9:E1372012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brown M, Hart C, Tawadros T, et al: The
differential effects of statins on the metastatic behaviour of
prostate cancer. Br J Cancer. 106:1689–1696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Parada B, Reis F, Pinto A, et al:
Chemopreventive efficacy of atorvastatin against
nitrosamine-induced rat bladder cancer: antioxidant,
anti-proliferative and anti-inflammatory properties. Int J Mol Sci.
13:8482–8499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lai SW, Liao KF, Lai HC, et al:
Atorvastatin correlates with decreased risk of esophageal cancer: a
population-based case-control study from Taiwan. Libyan J Med.
7:188302012.PubMed/NCBI
|
|
40
|
Miyamoto S, Purcell NH, Smith JM, et al:
PHLPP-1 negatively regulates Akt activity and survival in the
heart. Circ Res. 107:476–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nitsche C, Edderkaoui M, Moore RM, et al:
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer
cell death, and inhibits tumor formation. Gastroenterology.
142:377–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mulholland DJ, Tran LM, Li Y, et al: Cell
autonomous role of PTEN in regulating castration-resistant prostate
cancer growth. Cancer Cell. 19:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee JK, Edderkaoui M, Truong P, et al:
NADPH oxidase promotes pancreatic cancer cell survival via
inhibiting JAK2 dephosphorylation by tyrosine phosphatases.
Gastroenterology. 133:1637–1648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mistafa O, Ghalali A, Kadekar S, et al:
Purinergic receptor-mediated rapid depletion of nuclear
phosphorylated Akt depends on pleckstrin homology domain
leucine-rich repeat phosphatase, calcineurin, protein phosphatase
2A, and PTEN phosphatases. J Biol Chem. 285:27900–27910. 2010.
View Article : Google Scholar
|
